The 2014 amendment to the FDA’s regulations governing the content and format of labeling for human prescription drugs and biological products also requires the inclusion of a “Females and Males of Reproductive Potential” subsection.2,3 The subsection provides guidance when pregnancy testing or contraception is required or recommended before, during, or after drug therapy; or when there are human or animal data that suggest drug-associated fertility effects.
Your session is about to expire. Do you want to continue logged in?
WARNING! You did not finish creating your certificate. Please click CONTINUE below to return to your previous page to complete the process. Failure to complete ALL the steps will result in a loss of this test score, and you will not receive credit for this course.